Updated 12:17 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 58,232.43 -0.96%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $58,232 −0.96% VIX 35.89 +26.20% latest tape · as of 12:17 UTC
The Screen · Healthcare · Biotechnology

Alpha Tau Medical Ltd.

DRTS · Nasdaq · USD · Market cap $1.1B · 121 employees

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.

FAIL · Does not pass the screen
11.76 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price11.76 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 8.18)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $16.00 to $23.51, base estimate $18.00 (screen dated 2026-11-20).

Current read
Markup ?
Undervalued · screened 2026-11-20
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 8.18, read 2026-11-20
  • Ethical does not pass the values gate
Price11.76 USD
Fair value18.00
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-12Read Markup14.02-16.2% to today Distribution gives way to Markup first Markup read since August
2026-11-08Read Distribution13.72-14.3% to today ✓Markdown gives way to Distribution
2026-10-11Read Markdown14.00-16.0% to today ✓Accumulation gives way to Markdown after an 8% slide in 9 days
2026-10-02Read Accumulation15.14-22.4% to today Markup gives way to Accumulation after a 54% rise in 13 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Alpha Tau Medical Ltd. holds its Markup at $11.76. The statistical read favours the sellers, held for 63 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateThe statistical read favours the sellers, held for 63 days
Price at the screen$11.76
ValuationN/A trailing · -21.88 forward price to earnings
Values screenFAIL · score 70.0
Beta1.29
The Workings

Five Screens: DRTS's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 12.99% Below 33% Pass
Interest-bearing cash 57.66% Below 33% Fail
Receivables 11.87% Below 49% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Alpha Tau Medical's business is fine, but its cash and interest-bearing securities are about 58% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when DRTS's ethical verdict changes

Today DRTS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 35% discount to our $18.00 fair value.

Method.

16.00Conservative18.00Base case23.51Growth case 11.76Price

USD, 2026-11-20 screen. A 34.7% under base.

The Street's Range
16.00Street low 18.00Street average 30.00Street high 11.76Price

Street: 5 covering, consensus Strong Buy. Average target +53%.

Chart
The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-21.9x
EPS, trailing-1.04
EPS, forward-0.54
Profit margin0.0%currently unprofitable
Return on equity-141.7%not currently earning a positive return on equity
FCF yield-1.86%
Debt to equity0.34minimal debt: a conservative balance sheet
Current ratio11.09comfortably covers its short-term bills
Beta1.29moves a little more than the market
Short interest, float0.06%
52-week range3.43 - 15.79
Market cap$1.1B
Employees121

DRTS-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Israel and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $12.01 +0.0% Entry 20
2026-11-19 Markup $12.01 -0.7% Entry 19
2026-11-18 Markup $12.09 -9.6% Entry 18
2026-11-17 Markup $13.38 +0.0% Entry 17
2026-11-16 Markup $13.38 +0.0% Entry 16
2026-11-15 Markup $13.38 +0.0% Entry 15
2026-11-14 Markup $13.38 +0.1% Entry 14
2026-11-13 Markup $13.36 -4.7% Entry 13
2026-11-12 Markup · changed $14.02 +2.2% Entry 12

The framework has shifted from distribution to markup since the last review. Earnings landed in this window.

2026-11-08 Distribution · changed $13.72 +5.1% Entry 11

The framework has shifted from markdown to distribution since the last review. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on DRTS

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in DRTS's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $10.34 -11.8% · $882 -11.8%
2 months $7.29 +25.1% · $1,251 +25.1%
3 months $6.97 +30.9% · $1,309 +30.9%
6 months $4.96 +83.9% · $1,839 +83.9%
1 year $3.09 +195.2% · $2,952 +195.2%
2 years $2.38 +283.2% · $3,832 +283.2%
3 years $4.00 +128.0% · $2,280 +128.0%
5 years $9.65 -5.5% · $945 -5.5%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever DRTS does next, these words stay.

Alpha Tau Medical Ltd. · DRTS · Markup · $11.76
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.